NNC0487-0111 A

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

ObesityOverweight

Phase 1

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

CompletedNCT05369390

Novo Nordisk A/SObesity

Start: 2022-05-11End: 2024-01-09Updated: 2025-06-15

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

CompletedNCT06461039

Novo Nordisk A/SObesity

Start: 2024-06-14End: 2025-04-04Updated: 2025-05-08

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

CompletedNCT07121153

Novo Nordisk A/SObesity, Overweight

Start: 2025-08-11End: 2025-12-20Updated: 2026-02-17

Related Papers

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

2025-06-2010 citations